Drug intelligence / Profile preview

IM73 CAR-T

Development stage: Unknown
Lead developer: Memorial Sloan Kettering Cancer Center
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

IM73 CAR-T is an investigational allogeneic chimeric antigen receptor T cell (CAR-T) therapy developed for the treatment of acute myeloid leukemia (AML). The therapy involves donor-derived T cells engineered to express a CAR targeting both CD33 and CLL-1, two antigens commonly expressed on AML cells. This bivalent targeting is designed to increase specificity for malignant cells, aiming to overcome challenges posed by antigen heterogeneity in AML. IM73 CAR-T is intended for adult patients with relapsed or refractory AML and is under clinical evaluation to assess its safety and efficacy[7].

Targets

CLEC12ACD33 (Myeloid cell surface antigen CD33)

Beyond the preview

Go deeper on IM73 CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IM73 CAR-T.

Explore the full profile